One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
In Clinical Care, What Will Amazon Deliver?
Elizabeth Rourke, M.D.
doi : 10.1056/NEJMp2113702
N Engl J Med 2021; 385:2401-2403
Covid-19 Vaccination in American Indians and Alaska Natives — Lessons from Effective Community Responses
Raymond Foxworth, Ph.D., Nicole Redvers, N.D., M.P.H., Marcos A. Moreno, M.D., Victor A. Lopez-Carmen, M.P.H., Gabriel R. Sanchez, Ph.D., and James M. Shultz, Ph.D.
doi : 10.1056/NEJMp2113296
N Engl J Med 2021; 385:2403-2406
Tobacco-free Nicotine — New Name, Same Scheme?
Sam N. Cwalina, B.S., Rob McConnell, M.D., Neal L. Benowitz, M.D., and Jessica L. Barrington-Trimis, Ph.D.
doi : 10.1056/NEJMp2111159
N Engl J Med 2021; 385:2406-2408
A Divisive Ruling on Devices — Genus Medical Technologies v. FDA
Patricia J. Zettler, J.D., Eli Y. Adashi, M.D., and I. Glenn Cohen, J.D.
doi : 10.1056/NEJMp2117295
N Engl J Med 2021; 385:2409-2411
Relief in Sight — Estimated Savings under Medicare Part D Redesign
Stacie B. Dusetzina, Ph.D.
doi : 10.1056/NEJMp2116586
N Engl J Med 2021; 385:e93
BNT162b2 Vaccine Booster and Mortality Due to Covid-19
Ronen Arbel, Ph.D., Ariel Hammerman, Ph.D., Ruslan Sergienko, M.A., Michael Friger, Ph.D., Alon Peretz, M.D., Doron Netzer, M.D., and Shlomit Yaron, M.D.
doi : 10.1056/NEJMoa2115624
N Engl J Med 2021; 385:2413-2420
The emergence of the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 and the reduced effectiveness over time of the BNT162b2 vaccine (Pfizer–BioNTech) led to a resurgence of coronavirus disease 2019 (Covid-19) cases in populations that had been vaccinated early. On July 30, 2021, the Israeli Ministry of Health approved the use of a third dose of BNT162b2 (booster) to cope with this resurgence. Evidence regarding the effectiveness of the booster in lowering mortality due to Covid-19 is still needed.
Protection against Covid-19 by BNT162b2 Booster across Age Groups
Yinon M. Bar-On, M.Sc., Yair Goldberg, Ph.D., Micha Mandel, Ph.D., Omri Bodenheimer, M.Sc., Laurence Freedman, Ph.D., Sharon Alroy-Preis, M.D., Nachman Ash, M.D., Amit Huppert, Ph.D., and Ron Milo, Ph.D.
doi : 10.1056/NEJMoa2115926
N Engl J Med 2021; 385:2421-2430
After promising initial results from the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) to persons 60 years of age or older, the booster campaign in Israel was gradually expanded to persons in younger age groups who had received a second dose at least 5 months earlier.
Trial of Spesolimab for Generalized Pustular Psoriasis
Hervé Bachelez, M.D., Ph.D., Siew-Eng Choon, F.R.C.P., Slaheddine Marrakchi, M.D., A. David Burden, M.D., Tsen-Fang Tsai, M.D., Akimichi Morita, M.D., Alexander A. Navarini, M.D., Ph.D., Min Zheng, M.D., Ph.D., Jinhua Xu, M.D., Ph.D., Hamida Turki, M.D., Milan J. Anadkat, M.D., Sushmita Rajeswari, M.Sc., Hairui Hua, Ph.D., Sebastian D. Vulcu, M.D., David Hall, Ph.D., Kay Tetzlaff, M.D., Christian Thoma, M.D., and Mark G. Lebwohl, M.D. for the Effisayil 1 Trial Investigators*
doi : 10.1056/NEJMoa2111563
N Engl J Med 2021; 385:2431-2440
Generalized pustular psoriasis (GPP) is a rare, life-threatening, inflammatory skin disease characterized by widespread eruption of sterile pustules. Interleukin-36 signaling is involved in the pathogenesis of this disorder. Spesolimab, a humanized anti–interleukin-36 receptor monoclonal antibody, is being studied for the treatment of GPP flares.
Multicomponent Strategy with Decentralized Molecular Testing for Tuberculosis
Adithya Cattamanchi, M.D., Tania F. Reza, M.P.P., Talemwa Nalugwa, M.B.A., Katherine Adams, M.P.H., Mariam Nantale, B.B.L.T., Denis Oyuku, P.G.D.M.E., Sarah Nabwire, B.S.W.A.S.A., Diana Babirye, M.Sc., Stavia Turyahabwe, M.P.H., Austin Tucker, M.H.S., Hojoon Sohn, Ph.D., Olivia Ferguson, M.Sc., Ryan Thompson, M.S.P.H., Priya B. Shete, M.D., Margaret A. Handley, Ph.D., Sara Ackerman, Ph.D., Moses Joloba, Ph.D., David A.J. Moore, M.D., J. Lucian Davis, M.D., David W. Dowdy, M.D., Katherine Fielding, Ph.D., and Achilles Katamba, Ph.D.
doi : 10.1056/NEJMoa2105470
N Engl J Med 2021; 385:2441-2450
Effective strategies are needed to facilitate the prompt diagnosis and treatment of tuberculosis in countries with a high burden of the disease.
Immune and Genome Engineering as the Future of Transplantable Tissue
Jennifer Elisseeff, Ph.D., Stephen F. Badylak, M.D., D.V.M, Ph.D., and Jef D. Boeke, Ph.D., D.Sc.
doi : 10.1056/NEJMra1913421
N Engl J Med 2021; 385:2451-2462
Minocycline-Induced Hyperpigmentation
Sho Katayama, M.D., and Mitsuhito Ota, M.D., Ph.D.
doi : 10.1056/NEJMicm2111130
N Engl J Med 2021; 385:2463
Pupillary Light–Near Dissociation
Emanuele La Corte, M.D., Ph.D., and Matteo Martinoni, M.D.
doi : 10.1056/NEJMicm2031597
N Engl J Med 2021; 385:e94
Case 39-2021: A 26-Year-Old Woman with Respiratory Failure and Altered Mental Status
Aran Kadar, M.D., Viral S. Shah, M.D., Dexter P. Mendoza, M.D., Peggy S. Lai, M.D., Yasmin Aghajan, M.D., Gregory Piazza, M.D., Erica C. Camargo, M.D., and Kartik Viswanathan, M.D., Ph.D.
doi : 10.1056/NEJMcpc2107355
N Engl J Med 2021; 385:2464-2474
Booster Doses and Prioritizing Lives Saved
Minal K. Patel, M.D.
doi : 10.1056/NEJMe2117592
N Engl J Med 2021; 385:2476-2477
Audio Interview: A Potential New Agent to Treat Covid-19
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2119792
N Engl J Med 2021; 385:e101
Consultative Medicine — An Emerging Specialty for Patients with Perplexing Conditions
Linda N. Geng, M.D., Ph.D., Abraham Verghese, M.D., and Jon C. Tilburt, M.D.
doi : 10.1056/NEJMms2111017
N Engl J Med 2021; 385:2478-2484
Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
doi : 10.1056/NEJMc2115597
N Engl J Med 2021; 385:2485-2487
Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections
doi : 10.1056/NEJMc2108120
N Engl J Med 2021; 385:2487-2489
Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons
doi : 10.1056/NEJMc2102507
N Engl J Med 2021; 385:2489-2491
Salt Substitute and Cardiovascular Events and Death
doi : 10.1056/NEJMc2116824
N Engl J Med 2021; 385:2491-2494
Lutetium-177–PSMA-617 for Prostate Cancer
doi : 10.1056/NEJMc2116647
N Engl J Med 2021; 385:2494-2496
